DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson’s disease patients

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Parkinson J. An essay on the shaking palsy. 1817. J. Neuropsychiatry Clin. Neurosci.14(2),223–236 (2002).
  MedlineGoogle Scholar
• 2  Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP. Epidemiology of Parkinson’s disease. J. Neurol.255(Suppl. 5),S18–S32 (2008).
  MedlineGoogle Scholar
• 3  Lewis SJ, Caldwell MA, Barker RA. Modern therapeutic approaches in Parkinson’s disease. Expert Rev. Mol. Med.5(10),1–20 (2003).
  MedlineGoogle Scholar
• 4  Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest.116(7),1744–1754 (2006).
  Medline CASGoogle Scholar
• 5  Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord.16(3),448–458 (2001).
  Medline CASGoogle Scholar
• 6  Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet1(8007),345–349 (1977).
  Medline CASGoogle Scholar
• 7  Denny AP, Behari M. Motor fluctuations in Parkinson’s disease. J. Neurol. Sci.165(1),18–23 (1999).
  Medline CASGoogle Scholar
• 8  Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976–1990. Arch. Neurol.63(2),205–209 (2006).
  MedlineGoogle Scholar
• 9  Ku S, Glass GA. Age of Parkinson’s disease onset as a predictor for the development of dyskinesia. Mov. Disord.25(9),1177–1182 (2010).
  MedlineGoogle Scholar
• 10  Sharma JC, Bachmann CG, Linazasoro G. Classifying risk factors for dyskinesia in Parkinson’s disease. Parkinsonism Relat. Disord.16(8),490–497 (2010).
  Medline CASGoogle Scholar
• 11  Oliveri RL, Annesi G, Zappia M et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology53(7),1425–1430 (1999).▪ First study to investigate pharmacogenetics of levodopa-induced dyskinesia.
  Medline CASGoogle Scholar
• 12  Kaiser R, Hofer A, Grapengiesser A et al.L-dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology60(11),1750–1755 (2003).
  Medline CASGoogle Scholar
• 13  Zappia M, Annesi G, Nicoletti G et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch. Neurol.62(4),601–605 (2005).
  MedlineGoogle Scholar
• 14  Lee JY, Cho J, Lee EK, Park SS, Jeon BS. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson’s disease. Mov. Disord.26(1),73–79 (2011).
  MedlineGoogle Scholar
• 15  Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum. Mutat.23(6),540–545 (2004).▪▪ First time that TaqIA polymorphism was linked with ANKK1 gene.
  Medline CASGoogle Scholar
• 16  Hoenicka J, Quinones-Lombrana A, Espana-Serrano L et al. The ANKK1 gene associated with addictions is expressed in astroglial cells and upregulated by apomorphine. Biol. Psychiatry67(1),3–11 (2010).
  Medline CASGoogle Scholar
• 17  Huang W, Payne TJ, Ma JZ et al. Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African–American sample. Neuropsychopharmacology34(2),319–330 (2009).
  Medline CASGoogle Scholar
• 18  Bontempi S, Fiorentini C, Busi C, Guerra N, Spano P, Missale C. Identification and characterization of two nuclear factor-κB sites in the regulatory region of the dopamine D2 receptor. Endocrinology148(5),2563–2570 (2007).
  Medline CASGoogle Scholar
• 19  Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry55(3),181–184 (1992).
  Medline CASGoogle Scholar
• 20  Martínez-Martín P, Gil-Nagel A, Gracia LM, Gómez JB, Martínez-Sarriés J, Bermejo F. Unified Parkinson’s disease rating scale characteristics and structure. The Cooperative Multicentric Group. Mov. Disord.9(1),76–83 (1994).
  Medline CASGoogle Scholar
• 21  Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum. Mol. Genet.6(4),577–582 (1997).
  Medline CASGoogle Scholar
• 22  Long JC, Williams RC, Urbanek M. An E–M algorithm and testing strategy for multiple locus haplotypes. Am. J. Hum. Genet.56(3),799–810 (1995).
  Medline CASGoogle Scholar
• 23  Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet.68(4),978–989 (2001).
  Medline CASGoogle Scholar
• 24  Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am. J. Hum. Genet.76(3),449–462 (2005).
  Medline CASGoogle Scholar
• 25  Jonsson EG, Nothen MM, Grunhage F et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry4(3),290–296 (1999).
  Medline CASGoogle Scholar
• 26  Paus S, Seeger G, Brecht HM et al. Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson’s disease. Mov. Disord.19(6),705–707 (2004).
  MedlineGoogle Scholar
• 27  Zhang Y, Bertolino A, Fazio L et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc. Natl Acad Sci. USA104(51),20552–20557 (2007).
  Medline CASGoogle Scholar
• 28  Yang BZ, Kranzler HR, Zhao H, Gruen JR, Luo X, Gelernter J. Association of haplotypic variants in DRD2, ANKK1, TTC12 and NCAM1 to alcohol dependence in independent case control and family samples. Hum. Mol. Genet.16(23),2844–2853 (2007).
  Medline CASGoogle Scholar
• 29  McGuire V, Van Den Eeden SK, Tanner CM et al. Association of DRD2 and DRD3 polymorphisms with Parkinson’s disease in a multiethnic consortium. J. Neurol. Sci.307(1–2),22–29 (2011).
  Medline CASGoogle Scholar
• 30  Jomphe C, Tiberi M, Trudeau LE. Expression of D2 receptor isoforms in cultured neurons reveals equipotent autoreceptor function. Neuropharmacology50(5),595–605 (2006).
  Medline CASGoogle Scholar
• 31  Benoit-Marand M, Borrelli E, Gonon F. Inhibition of dopamine release via presynaptic D2 receptors: time course and functional characteristics in vivo. J. Neurosci.21(23),9134–9141 (2001).▪▪ Study that clarifies the physiological function of the DRD2 autoreceptor as a dopamine autoinhibitor.
  Medline CASGoogle Scholar
• 32  Duan J, Wainwright MS, Comeron JM et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum. Mol. Genet.12(3),205–216 (2003).
  Medline CASGoogle Scholar
• 33  Hirvonen MM, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J. C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol. Psychiatry9(12),1060–1061 (2004).
  Medline CASGoogle Scholar
• 34  Hirvonen MM, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J. C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol. Psychiatry.10(9),889 (corrigendum) (2005).
  CASGoogle Scholar
• 35  Hirvonen MM, Lumme V, Hirvonen J et al. C957T polymorphism of the human dopamine D2 receptor gene predicts extrastriatal dopamine receptor availability in vivo. Prog. Neuropsychopharmacol Biol. Psychiatry33(4),630–636 (2009).
  Medline CASGoogle Scholar
• 36  Hirvonen MM, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J. C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse63(10),907–912 (2009).
  Medline CASGoogle Scholar
• 37  Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch. Gen. Psychiatry48(7),648–654 (1991).
  Medline CASGoogle Scholar
• 38  Thompson J, Thomas N, Singleton A et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics7(6),479–484 (1997).
  Medline CASGoogle Scholar
• 39  Pohjalainen T, Rinne JO, Nagren K et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatry3(3),256–260 (1998).
  Medline CASGoogle Scholar
• 40  Ritchie T, Noble EP. Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem. Res.28(1),73–82 (2003).
  Medline CASGoogle Scholar
• 41  Laruelle M, Gelernter J, Innis RB. D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene. Mol. Psychiatry3(3),261–265 (1998).
  Medline CASGoogle Scholar
• 42  Laakso A, Pohjalainen T, Bergman J et al. The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjects. Pharmacogenet. Genomics15(6),387–391 (2005).
  Medline CASGoogle Scholar
• 43  Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D. Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson’s disease. Pharmacogenomics J.4(5),291–306 (2004).▪ Review of candidate genes that might confer idiopathic Parkinson’s disease susceptibility.
  Medline CASGoogle Scholar
• 44  Dubertret C, Gouya L, Hanoun N et al. The 3´ region of the DRD2 gene is involved in genetic susceptibility to schizophrenia. Schizophr. Res.67(1),75–85 (2004).
  MedlineGoogle Scholar
• 45  Arbouw ME, Van Vugt JP, Egberts TC, Guchelaar HJ. Pharmacogenetics of antiparkinsonian drug treatment: a systematic review. Pharmacogenomics8(2),159–176 (2007).▪ Review of pharmacogenetic studies in Parkinson’s disease.
  CASGoogle Scholar
• 46  Ponce G, Perez-Gonzalez R, Aragues M et al. The ANKK1 kinase gene and psychiatric disorders. Neurotox. Res.16(1),50–59 (2009).
  Medline CASGoogle Scholar
• 47  Koning JP, Vehof J, Burger H et al. Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. Psychopharmacology (Berl.).219(3),727–736 (2012).
  Medline CASGoogle Scholar
• 48  Wang J, Liu ZL, Chen B. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology56(12),1757–1759 (2001).
  Medline CASGoogle Scholar
• 49  Marsden CD, Parkes JD. “On-off” effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet1(7954),292–296 (1976).
  Medline CASGoogle Scholar
• 50  Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov. Disord.20(Suppl. 11),S11–S16 (2005).
  MedlineGoogle Scholar
• 51  Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson’s disease. Neurology55(11 Suppl. 4),S13–S20; discussion S21–S13 (2000).
  Medline CASGoogle Scholar
• 52  Fox SH, Lang AE. Levodopa-related motor complications – phenomenology. Mov. Disord.23(Suppl. 3),S509–S514 (2008).
  MedlineGoogle Scholar
• 53  Colosimo C, Martínez-Martín P, Fabbrini G et al. Task force report on scales to assess dyskinesia in Parkinson’s disease: critique and recommendations. Mov. Disord.25(9),1131–1142 (2010).
  MedlineGoogle Scholar
• 54  Santos NP, Ribeiro-Rodrigues EM, Ribeiro-Dos-Santos AK et al. Assessing individual interethnic admixture and population substructure using a 48-insertion-deletion (INSEL) ancestry-informative marker (AIM) panel. Hum. Mutat.31(2),184–190 (2010).
  Medline CASGoogle Scholar
• 55  Cheshire PA, Williams DR. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson’s disease. J. Clin. Neurosci.19(3),343–348 (2012).
  Medline CASGoogle Scholar
• 56  Fuxe K, Ferré S, Canals M et al. Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. J. Mol. Neurosci.26(2–3),209–220 (2005).
  Medline CASGoogle Scholar
• 57  Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA. Role of adenosine A2A receptors in parkinsonian motor impairment and L-DOPA-induced motor complications. Prog. Neurobiol.83(5),293–309 (2007).
  Medline CASGoogle Scholar
• 58  Hickey P, Stacy M. Adenosine A2A antagonists in Parkinson’s disease: what’s next? Curr. Neurol. Neurosci. Rep.12(4),376–385 (2012).
  Medline CASGoogle Scholar
• 59  Popat RA, Van Den Eeden SK, Tanner CM et al. Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease. Eur. J. Neurol.18(5),756–765 (2011).
  Medline CASGoogle Scholar
• 60  Greenbaum L, Cohen OS, Inzelberg R et al. Association of the adenosine receptor A2A (ADORA2A) gene with L-dopa induced dyskinesia in Parkinson’s disease. Mov. Disord.27(Suppl. 1),S1385 (2012) (Abstract).
  Google Scholar